CAL-101is a potent and selective PI3K p110δ inhibitor with an IC50 of 2.5 nM. This compound induces selective cytotoxicity in CLL cells and is independent of IgVH mutational status. CAL--101 also acts as an antagonist in CD40L-mediated CLL cell survival.
1. Herman, S.E. et al. 2010. Blood. 116(12): 2078-2088. PMID: 20522708 2. Lannutti, B.J. et al. 2011. Blood. 117(2): 591-594. PMID: 20959606 3. Meadows, S.A. et al. 2012. Blood. 119(8): 1897-1900. PMID: 22210877 4. Xu, H. et al. 2013. Nature. 496(7446): 523-527. PMID: 23619696 5. Chiron, D. et al. 2014. Cancer Discov. 4(9): 1022-1035. PMID: 25082755 6. Boucrot, E. et al. 2015. Nature. 517(7535): 460-465. PMID: 25517094 7. Mounayar, M. et al. 2015. Stem Cells. 33(6): 1892-1901. PMID: 25753288
Soluble in water (<1 mg/ml at 25 °C), DMSO (83 mg/ml at 25 °C), ethanol (35 mg/ml at 25 °C), and 30% PEG400/0.5% Tween80/5% propylene glycol (30 mg/ml at 25 °C).
Store at -20° C
296.57° C (Predicted)
~599.1° C at 760 mmHg (Predicted)
~1.5 g/cm3 (Predicted)
pKb: 6.23 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of
FiorcariFiorcari, S. et al. (PubMed 24376763) reported that the PI3-kinase delta inhibitor Idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. -SCBT Publication Review
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn